'Cumulative incidence' diaporamas de présentation

993 views • 65 slides

Antiplatelet Therapy for Secondary Prevention in the First Year Following an Acute Coronary Syndr

Antiplatelet Therapy for Secondary Prevention in the First Year Following an Acute Coronary Syndrome. Canadian Cardiovascular Society Antiplatelet Guidelines.

752 views • 49 slides

Principles of Communicable Diseases Epidemiology

Principles of Communicable Diseases Epidemiology. Objectives. Definition of epidemiology The epidemiologic triad Definition of communicable diseases Importance of studying communicable diseases epidemiology Terminology Dynamics of disease transmission (chain of infection):

1.61k views • 45 slides

Diabetes Mellitus - The Old and the New

647 views • 45 slides

Epidemiologic Study Design: Cohort and Case-Control Studies

725 views • 42 slides

Breast Cancer Update

Breast Cancer Update. Miss B.N. Shah Consultant Surgeon Ealing Hospital. Current Incidence of breast cancer. Common disease 8% risk of development up to 74y Varies between countries Rare <20y 25 per 100,000 from 30-34y 200 per 100,000 from 45-50y 463 per 100,000 from 70-79y .

599 views • 38 slides

Health Effects of Alpha Emitters (Mechanistic Basis)

Health Effects of Alpha Emitters (Mechanistic Basis) Antone L. Brooks Washington State University Tri-Cities Health Physics Society Spokane WA July 10-14, 2005 Past Assumptions About Exposure to Alpha Emitters Hit cell has large radiation dose and effect

995 views • 37 slides

Heparin-Induced Thrombocytopenia (HIT)

1.1k views • 35 slides

Main Points to be Covered

Main Points to be Covered. Difference between cumulative incidence based on proportion of persons at risk and incidence rate based on person-time Calculating person-time incidence rates Uses of person-time incidence rates Relation of prevalence to incidence Odds versus probability.

536 views • 34 slides

Lecture 3: Frequency How do we measure disease, define risks, and then make use of this information?

EPI-546 Block I. Lecture 3: Frequency How do we measure disease, define risks, and then make use of this information?. Mathew J. Reeves BVSc, PhD Associate Professor, Epidemiology. Objectives - Concepts. 1. Understand the concept of uncertainty, probability and odds

1.44k views • 29 slides

BRCA1 and BRCA2 Mutations and Breast Cancer:

761 views • 23 slides

363 views • 23 slides

CANCER REGISTRATION IN AFRICA ~ Dr D. M. Parkin IACR course, Entebbe, 11-12 th September 2005

397 views • 22 slides

The Safety and Tolerability of Atopaxar (E5555) in the Treatment of Patients with Acute Coronary Syndromes: The LANCE

The Safety and Tolerability of Atopaxar (E5555) in the Treatment of Patients with Acute Coronary Syndromes: The LANCELOT-ACS Trial.

361 views • 22 slides

Ryan M. Lanning , Sean L. Berry, Michael R. Folkert , and Kaled M. Alektiar

Quantitative Dosimetric Analysis Of Patterns Of Local Relapse After IMRT For Primary Extremity Soft Tissue Sarcomas. Ryan M. Lanning , Sean L. Berry, Michael R. Folkert , and Kaled M. Alektiar Dept. of Radiation Oncology and Medical Physics Memorial Sloan-Kettering Cancer Center.

348 views • 20 slides

Local and Distant Failure According to Mode of Local Control in Localized Ewing Sarcoma of Bone

Local and Distant Failure According to Mode of Local Control in Localized Ewing Sarcoma of Bone. Steven DuBois, MD UCSF Department of Pediatrics. Local Control in Ewing Sarcoma. Options for local control of primary tumor Definitive surgical resection Definitive radiation

363 views • 19 slides

Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention

Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention . JA Rassen, MA Mittleman, RJ Glynn, A Brookhart, S Schneeweiss

342 views • 13 slides

Statin Landmark Trials Across the Spectrum of Risk: Primary CV Prevention

Statin Landmark Trials Across the Spectrum of Risk: Primary CV Prevention. Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial. Deaths/10,000 patient-years. 34. Increasing Risk. N = 316,099. 23. 21. 18. 17. 17. 12. 13. 11. 14. 8.

215 views • 8 slides

Atorvastatin in Type 2 diabetics on dialysis: 4D Study

Atorvastatin in Type 2 diabetics on dialysis: 4D Study. 1255 T2DM patients on dialysis for 8.3 mo; 29% with prior MI or revascularization or CHD; 35% CHF; 45% PAD Baseline lipids: LDL-C 3.2 mmol /L;TG 3.0 mmol/L Atorva 20mg vs Pbo x 4 yrs; ? LDL-C: 1 mmol/L. 60.

345 views • 6 slides

152 views • 3 slides